SCHEDULE: 3i LP Increases Stake in Valion Bio

3i, LP reports an increase in beneficial ownership of Valion Bio, Inc. common stock to 9.9%, primarily through warrant exercises and convertible note/preferred stock conversions, subject to beneficial ownership limitations.

Summary

• This filing is an amendment (Amendment No. 7) to a Schedule 13D for Valion Bio, Inc. (the 'Issuer').
• The reporting persons include 3i, LP, Tumim Stone Capital, LLC, 3i Management LLC, and Maier J. Tarlow.
• As of August 24, 2026, the reporting persons beneficially own 132,671 shares of common stock, representing 9.9% of the class.
• This ownership is based on 1,285,626 shares outstanding after a 1-for-25 reverse stock split effective August 31, 2026.
• Beneficial ownership includes directly held shares, shares issuable from warrant exercises, convertible notes, Series B Preferred Stock, and Series C Preferred Stock, all subject to a 9.99% beneficial ownership limitation ('Blocker').
• A new transaction on September 3, 2026, involved 3i, LP purchasing 3,004 shares of common stock at $2.8808 per share.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative score due to the nature of a Schedule 13D filing, which typically indicates increased scrutiny or potential activist involvement rather than positive operational news.

Positives

• 3i, LP has increased its investment in Valion Bio, Inc., indicating continued confidence or strategic interest.
• The reporting persons have a clear understanding of the outstanding share count and beneficial ownership limitations.

Negatives

• The filing is an amendment to a Schedule 13D, which often signals increased scrutiny or potential activist investor activity, which can create uncertainty.
• The beneficial ownership is subject to a 9.99% 'Blocker' provision, limiting the ability to fully exercise warrants or convert securities without triggering a sale.
• The reporting persons do not hold any sole voting or dispositive power, with all beneficial ownership being shared.

Risks

• The 9.99% beneficial ownership limitation ('Blocker') restricts the reporting persons' ability to acquire more shares through warrant exercises or conversions without potentially being forced to sell shares.
• Schedule 13D filings can attract regulatory attention and may signal potential disputes or changes in corporate control, creating market uncertainty.

Future Outlook

The filing does not contain forward-looking statements or guidance. It primarily reports on current beneficial ownership and recent transactions.

Management Comments

• The beneficial ownership consists of shares directly held, and shares issuable upon exercise of warrants, conversions of a senior secured convertible note, Series B Convertible Preferred Stock, and Series C Convertible Preferred Stock, all subject to a 9.99% beneficial ownership limitation ('Blocker').
• All references to share and per share amounts give effect to the Issuer's 1-for-25 reverse stock split.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are common in the biotechnology sector, often indicating strategic investments, potential activist involvement, or the accumulation of significant stakes by investment funds seeking to influence corporate strategy or realize value through conversions and exits.

Stakeholder Impact

• Shareholders may experience increased volatility or uncertainty due to the increased stake and potential activist nature of the filing.
• The 'Blocker' provision may limit the ability of 3i, LP to convert its holdings, potentially impacting the dilution experienced by other shareholders if conversions were to occur without the blocker.

Next Steps

• The reporting persons will continue to monitor the Issuer's business and may take further actions regarding their investment, subject to the beneficial ownership limitations.

Key Dates

Recommendation

The filing indicates an increased stake by 3i, LP, but the presence of a 'Blocker' provision limits immediate upside from conversions and warrant exercises. The nature of a Schedule 13D suggests potential for future strategic moves, but without clear operational updates or positive financial news, a 'hold' position is prudent pending further developments.

Keywords

Valion Bio, Schedule 13D, 3i, LP, Beneficial Ownership, Warrants, Convertible Notes, Preferred Stock, Blocker Provision